The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting the ongoing M&A momentum in the life sciences sector, German company Merck KGaA announced a cash acquisition offer for Bio-Techne at $73 per share, valuing the deal at approximately $11.3 billion. The offer price represents a roughly 36% premium over the last closing price, sending shares surging over 22% in premarket trading.
The deal reflects Merck KGaA's confidence in Bio-Techne's growth potential in the life sciences sector, as it seeks to strengthen its footprint in biological tools and reagents. According to market data, Bio-Techne closed at $57.94 prior to the announcement, indicating a substantial premium. The acquisition comes amid a wave of large deals in the sector as companies aim to bolster their product portfolios.
Sign in to access this content
Sign InTechnically, Bio-Techne closed at $57.94 on June 18, and the stock is expected to trade near the offer price of $73 as the acquisition progresses. The deal is subject to shareholder and regulatory approvals and is expected to take several months. Investors should watch for regulatory developments and shareholder votes as key catalysts in the coming period.